BioSpace News Archive

Levicept Ltd announces it has completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent.

Dizal announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer patients with EGFR exon 20 insertion mutations were published in the peer-reviewed journal The Lancet Respiratory Medicine.

EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.

Many cancers caused by the mutation of the BRAF gene respond well to a class of immunotherapies known as BRAF-inhibitors. BRAF-mutated colorectal cancer, however, almost never does.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

MitoRx Therapeutics announces the final close of its seed extension financing round, with £4m raised to date from existing investors.

BioLabs and Promega announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.

Shattuck Labs, Inc. today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.

Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company for $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.

Centogene N.V. today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study , being conducted to advance the genetic understanding of frontotemporal dementia (FTD).